Market Overview

Equity Brief: Ratings Changes for November 8th: ABAX, ABFS, ADSK, ADTN, ALGN, AMNB, AOL, ARNA, ATK


A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Stifel Nicolaus initiated coverage on shares of Abaxis, Inc. (ABAX). They issued a buy rating on the stock and set a $44.00 price target.

Sterne Agee downgraded shares of Arkansas Best Corp (ABFS) from a neutral rating to an underperform rating.

Jefferies Group downgraded shares of Autodesk (ADSK) from a buy rating to a hold rating. Their analysts now have a $34.00 price target on the stock.

Mizuho upgraded shares of ADTRAN, Inc. (ADTN) from an underperform rating to a buy rating. Mizuho now has a $22.00 price target on the stock, up previously from $10.00.

Stifel Nicolaus initiated coverage on shares of Align Tech (ALGN). They issued a buy rating on the stock and set a $32.00 price target.

Raymond James upgraded shares of American National Bankshares Inc (AMNB) from a market perform rating to an outperform rating.

Jefferies Group gave shares of AOL (AOL) a new $50.00 price target. They now have a buy rating on the stock. They wrote, "We reiterate our BUY & raise PT to $50 on a 'Beat & Raise' 3Q driven by solid Network performance. Focus remains: 1) driving sustained top & bottom lines via strategic operational / financial improvements; 2) delivering concrete shareholder value (share count down ~30% / $5.15 dividend); and 3) leveraging investments in premium content, advertising and core services."

Jefferies Group gave shares of Arena Pharmaceuticals, Inc. (ARNA) a new $14.00 price target. They now have a buy rating on the stock. They wrote, "ARNA reiterated its plans for Belviq (1Q13 U.S. launch) and outlined a new South Korean partnership with Ildong. We remain confident in the long-term potential for Belviq based on combination use with phentermine, but we are lowering our PT from $20 to $14, as we moderate our launch expectations for Belviq monotherapy following disappointing sales for competitor Qsymia."

Standpoint Research downgraded shares of Alliant Techsystems Inc. (ATK) from an accumulate rating to a hold rating.

ISI Group upgraded shares of Bank of America (BAC) from a hold rating to a buy rating.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at http://bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net







This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Equity Brief via Thomson Reuters ONE

HUG#1656336

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters